Skip to Main Content

Paper Details

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.
Clin Cancer Res
26
2022
Author NameAffiliation
Martijn P LolkemaErasmus MC Cancer Center
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS, University of Milano
  • 1 - 2

Datasets

Release 1.2